9:00 9:15 | Welcome |
| Opening Remarks, Hans Scheurer, MPE President, and Ananda Plate, MPE CEO |
9.15 10.45 | AL Amyloidosis & other MM related diseases |
| Developments in AL amyloidosis: diagnostic centres of expertise, treatment pathway, and stages of the disease, Monique Minnema, MD, PhD University Medical Center Utrecht, the Netherlands |
| Myeloma related diseases, their presentation and effects on symptoms and quality of life, Paolo Milani, MD, PhD, University of Pavia, Pavia, Italy |
| Moderated Q&A |
10.45 11.00 | Coffee break |
11.00 12.30 | Access to new treatments |
| Immunotherapy in the treatment of myeloma and AL amyloidosis, Marivi Mateos |
| A clinical perspective on access in central and eastern European and Balkan countries, Roman Hájek, M.D., Ph.D., University Hospital Ostrava, Czech Republic |
| Moderated Q&A |
12.30 13.30 | Lunch break |
13.30 15.00 | Empowering Patient Organisations |
| Palliative Care and quality of life, Christina Gerlach, M.D. |
| Fundraising for patient groups and collaboration with industry, Jan Geissler, Chair, Workgroup of European Cancer Patient Advocacy Networks (WECAN) |
15:00 15:15 | Coffee Break |
15.15 16.45 | Panel discussion on Minimal Residual Disease (MRD) |
| Hans Jacobs, M.D., Ph.D., Medical Immunologist, Radboud University Medical Center, NL |
| Paula van Hennik, Committee for Medicinal Products for Human Use (CHMP) and member at the European Medicine Agency (EMA) |
| Hans Scheurer, MPE President |
16.45 17.00 | Wrap up and close, Hans Scheurer, MPE President, and Ananda Plate, MPE CEO |